抗体药物的全球增长机会

成本效益和高效的连续製造工艺和一次性生物反应器的使用，以及从开发到商业化的时间缩短，将推动全球抗体药物市场的发展。被认为免疫肿瘤领域已成为抗体药物市场的主要关注领域，尤其是随着高靶向抗体药物偶联物和双特异性抗体的出现。主要製造商正在寻求利用 CDMO 能力，相信市场格局在未来五年内可能会发生变化。

在完整的报告中，我们将调查全球抗体药物市场、市场背景、分析市场上的各种影响因素、管道、技术趋势、报销方案、收入趋势和预测、竞争环境、收入份额、分析增长机会等

内容

战略要务

• 为什么增长越来越难
• 战略要务 8(TM)
• 三大战略要务的市场影响
• 推动增长管道引擎 (TM) 的增长机会

增长机会分析

• 分析范围
• 分类/定义
• 技术细节的定义
• 增长驱动力
• 抑制增长的因素
• 要点

成长环境

• 抗体疗法：管线概览
• 晚期抗体药物的管线方案
• 潜在的治疗领域
• 价值链：主要利益相关者
• 主要抗体药物生产商
• 按地区划分的主要工业趋势
• 按管理途径划分的主要行业趋势
• 主要行业趋势：抗体药物偶联物
• 主要行业趋势：技术进步
• 抗体药价格分析
• 影响抗体药价格的因素
• 抗体药物的报销方案
• 抗体药物报销：区域概览
• 着名的抗体药物联盟与合作

收入预测

• 增长指标
• 调查方法
• 预测假设
• 收入预测
• 收入预测分析
• 收入预测：按技术分类
• 收入预测：按技术分类 - 讨论
• 竞争环境
• 收入份额分析
• 值得关注的主要 ADC 开发人员

增长机会领域

• 增长机会 1：开发针对癌症免疫的多特异性抗体
• 增长机会 2：与 CDMO 和平台提供商合作，进一步发展 ADC
• ADC 的主要联盟
• 增长机会 3：扩大单克隆抗体生物仿製药的可及性和适应症

The Evolution of Next-generation Immuno-oncology Therapies for Multiple Tumor Antigens is Poised to Drive Market Growth

Market growth is likely to be fueled by the growing utilization of cost-effective and efficient continuous manufacturing processes and single-use bioreactors for production, which will also reduce the time between development and commercialization. Favorable regulatory reforms in emerging Asian countries are encouraging the manufacture and introduction of monoclonal antibody-based biosimilars, aiming to reduce the cost-burden of originator antibody therapies. The tailored approach used by manufacturers to improve the targeting efficiency of drug molecules toward multiple antigens is strengthening the pipeline portfolio of SMEs in the antibodies space and accelerating the pace of antibody drug development for cancer treatment.

Immuno-oncology remains a key focus area in the antibody therapeutics market, especially due to the emergence of highly target-specific antibody-drug conjugates and bispecific antibodies. Key manufacturers are striving to reduce in-house operations to leverage the capabilities of contract development and manufacturing organizations (CDMOs) with the aim of boosting innovation in the industry, which is likely to change the face of the market over the next 5 years.

Research Scope:

This Frost & Sullivan research service offers an outlook of the global antibody therapeutics market for 2022 and beyond, highlighting emerging trends and growth opportunities. As innovation takes center stage, the market is likely to witness remarkable growth in the near future, attributable to the focus on bi- and multi-specific antibodies, which has augmented investments by emerging start-ups in this space. Moreover, adoption of the antibody drug co-development strategy by key market participants is rising; they use it to leverage technologically advanced drug discovery and development platforms, especially for non-standard antibody therapies, including antibody-drug conjugates.

Research Highlights:

• Conventional and recombinant antibody therapeutics market size, including key segments, from 2022 to 2027

• Dynamics around product innovation and the reimbursement scenario

• Regulatory reforms and technological advancements driving value chain transformation

• Current and future R&D efforts and investment outlook

• Growth opportunities that market participants can focus on in the near future

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Antibody Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation and Definition
• Definitions by Technology Subtype
• Growth Drivers
• Growth Restraints
• Key Takeaways

Growth Environment

• Antibody Therapeutics-Pipeline Snapshot
• Pipeline Scenario of Late-stage Antibody Therapeutics
• Potential Therapy Areas
• Value Chain-Key Stakeholders
• Key Antibody Therapeutics Manufacturers
• Key Industry Trends by Region
• Key Industry Trends by Region (continued)
• Key Industry Trends by Route of Administration
• Key Industry Trends-Antibody-Drug Conjugates
• Key Industry Trends-Technological Advancements
• Pricing Analysis of Antibody Therapeutics
• Factors Influencing the Pricing of Antibody Therapeutics
• Reimbursement Scenario for Antibody Therapeutics
• Reimbursement for Antibody Therapeutics-Regional Overview
• Notable Partnerships and Collaborations for Antibody Therapeutics
• Notable Partnerships and Collaborations for Antibody Therapeutics (continued)

Revenue Forecast

• Growth Metrics
• Research Methodology
• Forecast Assumptions
• Revenue Forecast
• Revenue Forecast Analysis
• Revenue Forecast by Technology
• Revenue Forecast by Technology Discussion
• Competitive Environment
• Revenue Share Analysis
• Key ADC Developers to Watch in 2022

Growth Opportunity Universe

• Growth Opportunity 1-Developing Multi-specific Antibodies for Immuno-oncology
• Growth Opportunity 1-Developing Multi-specific Antibodies for Immuno-oncology (continued)
• Growth Opportunity 2-Collaborating with CDMOs and Platform Providers for the Further Development of ADCs
• Growth Opportunity 2-Collaborating with CDMOs and Platform Providers for the Further Development of ADCs (continued)
• Key Alliances in ADCs
• Growth Opportunity 3-Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars
• Growth Opportunity 3-Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars (continued)
• List of Exhibits
• Legal Disclaimer